Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.5% – Time to Sell?

Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) fell 0.5% during trading on Tuesday . The company traded as low as $2.02 and last traded at $2.06. 28,760 shares traded hands during trading, a decline of 43% from the average session volume of 50,870 shares. The stock had previously closed at $2.07.

Analyst Upgrades and Downgrades

KPRX has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Friday, October 31st. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Kiora Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Zacks Research downgraded shares of Kiora Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.00.

Kiora Pharmaceuticals Price Performance

The company has a market capitalization of $7.58 million, a price-to-earnings ratio of -0.99 and a beta of -0.75. The company’s 50-day moving average price is $2.34 and its two-hundred day moving average price is $2.67.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its quarterly earnings results on Friday, November 7th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.73. On average, equities research analysts expect that Kiora Pharmaceuticals, Inc. will post 1.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Two Sigma Investments LP acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 11,984 shares of the company’s stock, valued at approximately $33,000. Two Sigma Investments LP owned approximately 0.33% of Kiora Pharmaceuticals as of its most recent SEC filing. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.